Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19048687 | 1.00 | HCAR2 (0.62) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL2118488 | 1.00 | HCAR2 (0.62) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL18288640 | 0.92 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL17092602 | 0.92 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL17092600 | 0.92 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL29822765 | 0.89 | HCAR2 (0.55) | HCAR2ATMMAPTLMNAPOLB | |
| Tepilamide Fumarate SCHEMBL17092614 | 0.85 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| Tepilamide Fumarate SCHEMBL15512161 | 0.85 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| Tepilamide Fumarate SCHEMBL2609690 | 0.85 | HCAR2 (0.48) | HCAR2ATMNPC1RAB9AMAPT | |
| SCHEMBL17108951 | 0.84 | HCAR2 (0.41) | HCAR2ATMNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114457-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2025-04-10 | — | — | US | claimed |
| US-20220241420-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | ARBOR PHARMACEUTICALS, LLC | 2022-08-04 | — | — | US | claimed |
| US-20190117776-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2019-04-25 | — | — | US | claimed |
| US-9999672-B2 | Pharmaceutical compositions of fumaric acid esters | XENOPORT, INC. (US) | 2018-06-19 | — | — | US | claimed |
| US-9452972-B2 | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof | XENOPORT, INC. (US) | 2016-09-27 | — | — | US | claimed |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | claimed |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2015-07-16 | — | — | US | claimed |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT INC (US) | 2014-11-06 | — | — | US | claimed |
| EP-2650279-A2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XenoPort, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| US-20250114457-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2025-04-10 | — | — | US | disclosed |
| US-20220241420-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | ARBOR PHARMACEUTICALS, LLC | 2022-08-04 | — | — | US | disclosed |
| US-11135296-B2 | Pharmaceutical compositions of fumaric acid esters | ARBOR PHARMACEUTICALS, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | ARBOR PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | ARBOR PHARMACEUTICALS, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135296-B2 | Pharmaceutical compositions of fumaric acid esters | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1025/4885ATM 4340/4885NPC1 756/4885 |
| US-20150197486-A9 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | HCAR2 68/4885ATM 2791/4885NPC1 4131/4885 |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | HCAR2 442/4885ATM 2577/4885NPC1 3828/4885 |
| US-20150265707-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1025/4885ATM 4340/4885NPC1 756/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | HCAR2 70/4885ATM 2335/4885NPC1 4208/4885 |
| US-10940117-B2 | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof | FH, MGMT, BHMT2 | HCAR2 442/4885ATM 2577/4885NPC1 3828/4885 |
| US-20250114457-A1 | PHARMACEUTICAL COMPOSITIONS OF FUMARIC ACID ESTERS | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1025/4885ATM 4340/4885NPC1 756/4885 |
| US-20220241420-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1025/4885ATM 4340/4885NPC1 756/4885 |
| US-20190117776-A1 | Pharmaceutical Compositions of Fumaric Acid Esters | FAH, FH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HCAR2 1025/4885ATM 4340/4885NPC1 756/4885 |
| US-20140329818-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | HCAR2 68/4885ATM 2791/4885NPC1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.